Keele, UK, 30 November 2004 – Cobra Biomanufacturing Plc (London Stock Exchange AIM) announced that it has appointed Nick Hill as Director of Quality and he will act as Qualified Person (QP). Nick joins Cobra from his most recent position as Technical Director at Bio-Products Laboratories, Elstree, UK and brings over 17 years experience in pharmaceutical manufacture and quality control.

Nick has worked for several leading international pharmaceutical and scientific companies including Bio-Products Laboratories, Washington Group International, Boehringer-Ingelheim and GSK. Nick will join Cobra’s existing QP staff and will be based at Cobra’s new Oxford facility.

“This appointment follows the commissioning of our new cGMP biomanufacturing facility in Oxford where we are manufacturing a range of diverse biologicals that include novel therapeutic proteins, viruses and DNA,” commented Dr David Thatcher, CEO, Cobra.

Under new EC legislation which came into effect earlier this year, the responsibility of a QP has increased substantially as they are now responsible for releasing all clinical trial materials that are produced in-house. In addition the QP has the authority to release imported materials for clinical trials that have been manufactured outside the EU by GMP.

Dr David Thatcher added, “We are delighted that Nick has joined Cobra, further strengthening our QP team and demonstrating our commitment to quality as a driver throughout the business.”

-Ends-

For further information please contact:

About Cobra Biomanufacturing Plc 

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the life science industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe.  A range of unique, patented technologies, underpins this revenue generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK.

www.cobrabio.com